Trial · NCT02859441
Adverse events27
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 27
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Ocular Hypertension | Eye disorders | E10030 and Ranibizumab | 1 | 3 | 3 |
| other | Back Pain | Musculoskeletal and connective tissue disorders | E10030 and Ranibizumab | 1 | 3 | 1 |
| other | Hypoaesthesia | Nervous system disorders | E10030 and Ranibizumab | 1 | 3 | 1 |
| other | Infection | Infections and infestations | E10030 and Ranibizumab | 1 | 3 | 1 |
| other | Posterior Capsule Opacification | Eye disorders | E10030 and Ranibizumab | 1 | 3 | 1 |
| other | Visual Acuity Reduced | Eye disorders | E10030 and Ranibizumab | 2 | 3 | 3 |
| other | Vomiting | Gastrointestinal disorders | E10030 and Ranibizumab | 1 | 3 | 1 |
| other | Weight Decreased | Investigations | E10030 and Ranibizumab | 1 | 3 | 1 |
| other | Eye Pain | Eye disorders | E10030 and Ranibizumab | 1 | 3 | 1 |
| other | Limb Injury | Injury, poisoning and procedural complications | E10030 and Ranibizumab | 1 | 3 | 1 |
| other | Vitreous Haemorrhage | Eye disorders | E10030 and Ranibizumab | 1 | 3 | 1 |
| other | Upper Respiratory Tract Inflammation | Respiratory, thoracic and mediastinal disorders | E10030 and Ranibizumab | 1 | 3 | 1 |
| other | Pyrexia | General disorders | E10030 and Ranibizumab | 1 | 3 | 1 |
| other | Corneal Abrasion | Eye disorders | E10030 and Ranibizumab | 1 | 3 | 1 |
| other | Keratopathy | Eye disorders | E10030 and Ranibizumab | 1 | 3 | 2 |
| other | Corneal Erosion | Eye disorders | E10030 and Ranibizumab | 1 | 3 | 1 |
| other | Corneal Neovascularization | Eye disorders | E10030 and Ranibizumab | 1 | 3 | 1 |
| other | Blood Pressure Increased | Investigations | E10030 and Ranibizumab | 1 | 3 | 1 |
| other | Retinal Haemorrhage | Eye disorders | E10030 and Ranibizumab | 1 | 3 | 1 |
| other | Von Hippel-Lindau Disease | Congenital, familial and genetic disorders | E10030 and Ranibizumab | 1 | 3 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02859441/events